Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Miguel Regueiro

Pittsburgh, PA Medical Doctor

NPI 1649245788 CMS profile 29594

200 Lothrop St, Digestive Disorders Center, Pittsburgh, PA 15213

Open in the dashboard

General payments

$1,511,279

864 records reported · program years 2019–2025

Research payments

$62,130

Paid to them · 45 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Miguel Regueiro of Pittsburgh, PA is reported in the CMS Open Payments database as having received $1,511,279 across 864 general payments and $62,130 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

By program year

13 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $222,923 122
2025 Research $4,470 3
2024 General $393,380 187
2024 Research $17,600 12
2023 General $276,931 149
2023 Research $17,020 13
2022 General $255,913 165
2022 Research $9,660 9
2021 General $146,747 82
2021 Research $6,980 6
2020 General $113,946 69
2020 Research $6,400 2
2019 General $101,440 90

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Miguel Regueiro
  • Pennsylvania median
  • Middle half of Pennsylvania
  • National median

In program year 2025, general payments to Miguel Regueiro were reported at $222,923. Among 44,217 Pennsylvania profiles paid that year, the median was $168 and the middle half received between $50 and $597.

Show as a table
Year Miguel Regueiro Pennsylvania median Middle half National median
2019 $101,440 $156 $46–$628 $163
2020 $113,946 $109 $33–$381 $114
2021 $146,747 $125 $35–$469 $132
2022 $255,913 $136 $40–$499 $149
2023 $276,931 $147 $46–$523 $160
2024 $393,380 $156 $46–$568 $164
2025 $222,923 $168 $50–$597 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $662,736 351 payments
  2. Janssen Biotech, Inc. $217,490 158 payments
  3. E.R. Squibb & Sons, L.L.C. $124,598 55 payments
  4. Pfizer Inc. $94,912 35 payments
  5. Takeda Pharmaceuticals U.S.A., Inc. $93,034 39 payments
  6. Eli Lilly and Company $87,634 68 payments
  7. Lilly USA, LLC $50,601 26 payments
  8. Janssen Scientific Affairs, LLC $48,459 22 payments
  9. Celgene Corporation $30,255 29 payments
  10. Genentech, Inc. $22,467 13 payments
  11. Other $79,094 68 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $954,500 298 payments
  2. Consulting Fee $474,289 157 payments
  3. Travel and Lodging $44,101 138 payments
  4. Honoraria $22,790 5 payments
  5. Food and Beverage $15,545 265 payments
  6. Education $55 1 payment
Products named General payments · program years 2019–2025
  1. RINVOQ $312,089 160 payments
  2. SKYRIZI Immunology $201,143 116 payments
  3. TREMFYA $181,401 119 payments
  4. STELARA $142,322 99 payments
  5. ZEPOSIA $133,800 74 payments
  6. OMVOH $96,517 37 payments
  7. HUMIRA $71,306 41 payments
  8. ENTYVIO $61,414 20 payments
  9. VELSIPITY $54,643 15 payments
  10. SKYRIZI Immunology $44,738 21 payments
  11. Other $58,156 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Pfizer Inc. $62,130 45 payments

Billing to Medicare

Part B · data year 2024 · 13 billing codes

Paid by Medicare

$6,318

Medicare's payments for the services billed

Medicare patients

38

Average age 69

Services billed

97

21 women, 17 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 66%
Arthritis 66%
Chronic kidney disease 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
SKYRIZI
$98,105 — —
OMVOH
$67,717 — —
RINVOQ
$58,099 — —
TREMFYA
$56,830 — —
VELSIPITY
$44,142 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

909 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record